The stock has a 36-month beta value of 0.02. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 6 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for MRVI is 115.94M, and at present, short sellers hold a 7.28% of that float. On September 05, 2024, the average trading volume of MRVI was 2.38M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MRVI) stock’s latest price update
Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) has seen a decline in its stock price by -6.30 in relation to its previous close of 8.73. However, the company has experienced a -9.41% decline in its stock price over the last five trading sessions. zacks.com reported 2024-08-29 that MRVI’s Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.
MRVI’s Market Performance
MRVI’s stock has fallen by -9.41% in the past week, with a monthly drop of -10.99% and a quarterly drop of -5.98%. The volatility ratio for the week is 4.82% while the volatility levels for the last 30 days are 7.82% for Maravai LifeSciences Holdings Inc The simple moving average for the past 20 days is -7.55% for MRVI’s stock, with a 7.52% simple moving average for the past 200 days.
Analysts’ Opinion of MRVI
Many brokerage firms have already submitted their reports for MRVI stocks, with Wells Fargo repeating the rating for MRVI by listing it as a “Overweight.” The predicted price for MRVI in the upcoming period, according to Wells Fargo is $10 based on the research report published on August 28, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see MRVI reach a price target of $10, previously predicting the price at $11. The rating they have provided for MRVI stocks is “Equal-Weight” according to the report published on August 13th, 2024.
Craig Hallum gave a rating of “Buy” to MRVI, setting the target price at $15 in the report published on April 10th of the current year.
MRVI Trading at -3.55% from the 50-Day Moving Average
After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.21% of loss for the given period.
Volatility was left at 7.82%, however, over the last 30 days, the volatility rate increased by 4.82%, as shares sank -10.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.70% upper at present.
During the last 5 trading sessions, MRVI fell by -9.41%, which changed the moving average for the period of 200-days by +57.61% in comparison to the 20-day moving average, which settled at $8.80. In addition, Maravai LifeSciences Holdings Inc saw 24.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRVI starting from GTCR INVESTMENT XI LLC, who sale 9,940,974 shares at the price of $9.81 back on May 28 ’24. After this action, GTCR INVESTMENT XI LLC now owns 20,150,005 shares of Maravai LifeSciences Holdings Inc, valued at $97,570,660 using the latest closing price.
Stock Fundamentals for MRVI
Current profitability levels for the company are sitting at:
- -0.16 for the present operating margin
- 0.42 for the gross margin
The net margin for Maravai LifeSciences Holdings Inc stands at -0.47. The total capital return value is set at -0.03. Equity return is now at value -27.59, with -7.12 for asset returns.
Based on Maravai LifeSciences Holdings Inc (MRVI), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at 0.06. The debt to equity ratio resting at 1.21. The interest coverage ratio of the stock is -1.57.
Currently, EBITDA for the company is 44.58 million with net debt to EBITDA at -1.64. When we switch over and look at the enterprise to sales, we see a ratio of 7.37. The receivables turnover for the company is 7.1for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.00.
Conclusion
To sum up, Maravai LifeSciences Holdings Inc (MRVI) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
